Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites

Journal of the National Cancer Institute

Volumn 85, Issue 10, 1993, Pages 806-812

  Wolf, Douglas M ^a   Langan fahey, Susan M ^a   Parker, Christopher J ^a   Mccague, Raymond ^b   Jordan, V Craig ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Cambridge Science Park ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; TAMOXIFEN; TAMOXIFEN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMAN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TREATMENT FAILURE; TUMOR CELLS, CULTURED;

EID: 0027280831     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.10.806     Document Type: Article

References (46)

1. Early Breast Cancer Trialjsts’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1992
2. O’Brian CA, Housey GM, Weinstein IB: Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 48:3626-3629, 1988
3. O’Brian CA, Liskimp RM, Soloman DH, et al: Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462-2465, 1985
4. Su HD, Mazzei GJ, Vogler WR, et al: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 34:3649-3658, 1985
5. Lam HYP: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Com-mun 118:27-32, 1984
6. Gulino A, Barrera G, Vacca A, et al: Calmodulin antagonism and growth-inhibiting activity of triphenylethylene antiestrogens in MCF-7 human breast cancer cells. Cancer Res 46:6274-6278, 1986
7. Greenberg DA, Carpenter CL, Messing RO: Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC 12 neurosecretory cell line. Cancer Res 47:70-74, 1987
8. Karey KP, Sirbasku DA: Differential responses of human breast cancer cell lines MCF-7 and T47D to growth factors and 173 estradiol. Cancer Res 48:4083-4092, 1988
9. van der Burg B, Rutteman GR, Blankenstein MA, et al: Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: Synergistic action of insulin and estrogen. J Cell Physiol 134:101-108, 1988
10. Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type 1 somatomedin receptor. Cancer Res 49:6237-6241, 1989
11. Colletti RB, Roberts JD, Devlin JT, et al: Effect of tamoxifen on plasma insulinlike growth factor I in patients with breast cancer. Cancer Res 49:1882-1884, 1989
12. POLLAK M, COSTANTINO J, POLYCHRONAKOS C, et al: Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693-1697, 1990
13. Friedl A, Jordan VC, Pollak M: Effect of tamoxifen (TAM) on insulin-like growth factor-1 (IGF-1) levels in breast cancer patients. Proc ASCO 11:52, 1992
14. Butta A, MacLennan K, Flanders KC, et al: Induction of transforming growth factor 31 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52:4261-4264, 1992
15. Jordan VC, Wolf MF, Mirecki DM, et al: Hormone receptor assays: Clinical usefulness in the management of carcinoma of the breast. Crit Rev Clin Lab Sci 26:97152, 1988
16. Wolf DM, Jordan VC: Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 45:118-128, 1992
17. Walker KJ, Price-Thomas JM, Candlish W, et al: Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 64:764-768, 1991
18. Shafie SM, Grantham FH: Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. JNCI 67:51-56, 1981
19. Osborne CK, Hobbs K, Clark GM: Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic mice. Cancer Res 45:584-590, 1985
20. Gottardis MM, Robinson SP, Jordan VC: Estradiol-stimulated growth of MCF-7 tumors, implanted in athymic mice: A model to study-the tumoristatic action of tamoxifen. J Steroid Biochem 30:311-314, 1988
21. Iino Y, Wolf DM, Langan-Fahey SM, et al: Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer 6:1019-1024, 1991
22. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: Cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23:1189-1196, 1987
23. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183-5187, 1988
24. Gottardis MM, Jiang SY, Jeng MH, et al: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090-4093, 1989
25. Osborne CK, Coronado E, Allred DC, et al: Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477-1482, 1991
26. Osborne CK, Wiebe VJ, McGuire WL, et al: Tamoxifen and the isomers of 4-hy-droxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304-310, 1992
27. Wiebe VJ, Osborne CK, McGuire WL, et al: Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10:990-994, 1992
28. Murphy CS, Langan-Fahey SM, McCague R, et al: Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. Mol Pharmacol 38:737-743, 1990
29. Jordan VC, Koch R, Langan S, et al: Ligand interaction at the estrogen receptor to program antiestrogen action: A study with nonsteroidal compounds in vitro. Endocrinology 122:1449-1454, 1988
30. McCague R, Kuroda R, Leclercq G, et al: Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-dimethyl-aminoethoxy]phenyl]5H-benzcycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. J Med Chem 29:2053-2058, 1986
31. McCague R, Leclercq G, Jordan VC: Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted di-phenylbenzocycloheptenes. J Med Chem 31:1285-1290, 1988
32. Murphy CS, Parker CJ, McCague R, et al: Structure-activity relationships of nonisomerizable derivatives of tamoxifen: Importance of hydroxyl group and side chain positioning for biological activity. Mol Pharmacol 39:421-428, 1991
33. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 26:883-888, 1990
34. Robinson SP, Langan-Fahey SM, Johnson DA, et al: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Disp 19:36-43, 1991
35. Jiang S-Y, Wolf DM, Yingling JM, et al: An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90:77-86, 1992
36. LaBarca C, Paigen K: A simple, rapid, and sensitive DNA assay procedure. Anal Bio-chem 102:344-352, 1980
37. Murphy LC, Dotzlaw H: Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3:687-693, 1989
38. co cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res 50:6208-6217, 1990
39. Fuqua SAW, Fitzgerald SD, Chamness GC, et al: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 41:105-109, 1991
40. Dotzlaw H, Alkhalaf M, Murphy LC: Characterization of estrogen receptor variant mRNAs from human breast cancers. Mol Endocrinol 6:773-785, 1992
41. Wilding G, Chen M, Gelmann EP: Aberrant responses in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14:103-115, 1989
42. Olea N, Sakabe K, Soto AM, et al: The proliferative effect of “anti-androgens” on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126:1457-1463, 1990
43. Schuurmans AL, Bolt J, Veldscholte J, et al: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Bio 37:849-853, 1990
44. Vegeto E, Allan GF, Schrader WT, et al: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713, 1992
45. Jiang S-Y, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84:580-591, 1992
46. Jiang S-Y, Langan-Fahey SM, Stella AL, et al: Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing cDNA’s for ER. Mol Endocrinol 6:2167-2174, 1992